nodes	percent_of_prediction	percent_of_DWPC	metapath
Carfilzomib—ABCB1—Mycophenolate mofetil—psoriasis	0.0317	0.168	CbGbCtD
Carfilzomib—ABCB1—Betamethasone—psoriasis	0.0272	0.144	CbGbCtD
Carfilzomib—ABCB1—Prednisolone—psoriasis	0.0268	0.142	CbGbCtD
Carfilzomib—ABCB1—Hydrocortisone—psoriasis	0.0254	0.135	CbGbCtD
Carfilzomib—ABCB1—Prednisone—psoriasis	0.0253	0.134	CbGbCtD
Carfilzomib—ABCB1—Cyclosporine—psoriasis	0.024	0.127	CbGbCtD
Carfilzomib—ABCB1—Dexamethasone—psoriasis	0.0158	0.0837	CbGbCtD
Carfilzomib—ABCB1—Methotrexate—psoriasis	0.0127	0.0672	CbGbCtD
Carfilzomib—PSMB2—skin epidermis—psoriasis	0.00998	0.371	CbGeAlD
Carfilzomib—PSMB1—skin of body—psoriasis	0.00317	0.118	CbGeAlD
Carfilzomib—PSMB8—tendon—psoriasis	0.00312	0.116	CbGeAlD
Carfilzomib—PSMB2—skin of body—psoriasis	0.00309	0.115	CbGeAlD
Carfilzomib—PSMB5—tendon—psoriasis	0.00276	0.103	CbGeAlD
Carfilzomib—PSMB1—tendon—psoriasis	0.00241	0.0897	CbGeAlD
Carfilzomib—PSMB2—tendon—psoriasis	0.00235	0.0875	CbGeAlD
Carfilzomib—PSMB9—Betamethasone—Clobetasol propionate—psoriasis	0.000945	0.0526	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Clobetasol propionate—psoriasis	0.000945	0.0526	CbGdCrCtD
Carfilzomib—Body temperature increased—Acitretin—psoriasis	0.000777	0.00225	CcSEcCtD
Carfilzomib—Headache—Methoxsalen—psoriasis	0.000777	0.00225	CcSEcCtD
Carfilzomib—Cardiac failure congestive—Prednisone—psoriasis	0.000776	0.00225	CcSEcCtD
Carfilzomib—Body temperature increased—Fluocinolone Acetonide—psoriasis	0.000775	0.00224	CcSEcCtD
Carfilzomib—Cardiac arrest—Betamethasone—psoriasis	0.000768	0.00222	CcSEcCtD
Carfilzomib—Cardiac arrest—Dexamethasone—psoriasis	0.000768	0.00222	CcSEcCtD
Carfilzomib—Infection—Hydroxyurea—psoriasis	0.000767	0.00222	CcSEcCtD
Carfilzomib—Back pain—Mycophenolic acid—psoriasis	0.000766	0.00222	CcSEcCtD
Carfilzomib—Muscle spasms—Mycophenolic acid—psoriasis	0.000761	0.0022	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Hydrocortisone—psoriasis	0.000759	0.0022	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Beclomethasone—psoriasis	0.000757	0.0421	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Fluocinonide—psoriasis	0.000757	0.0421	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Beclomethasone—psoriasis	0.000757	0.0421	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Fluocinonide—psoriasis	0.000757	0.0421	CbGdCrCtD
Carfilzomib—Diarrhoea—Calcitriol—psoriasis	0.000756	0.00219	CcSEcCtD
Carfilzomib—Thrombocytopenia—Hydroxyurea—psoriasis	0.000756	0.00219	CcSEcCtD
Carfilzomib—Nausea—Methoxsalen—psoriasis	0.000736	0.00213	CcSEcCtD
Carfilzomib—Anorexia—Hydroxyurea—psoriasis	0.000736	0.00213	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Prednisolone—psoriasis	0.000735	0.00213	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000735	0.0409	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000735	0.0409	CbGdCrCtD
Carfilzomib—Hypokalaemia—Dexamethasone—psoriasis	0.000735	0.00213	CcSEcCtD
Carfilzomib—Hypokalaemia—Betamethasone—psoriasis	0.000735	0.00213	CcSEcCtD
Carfilzomib—Hypoaesthesia—Cyclosporine—psoriasis	0.000732	0.00212	CcSEcCtD
Carfilzomib—Anaemia—Mycophenolic acid—psoriasis	0.000732	0.00212	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisolone—psoriasis	0.000731	0.00212	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Hydrocortisone—psoriasis	0.000718	0.00208	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Triamcinolone—psoriasis	0.000715	0.00207	CcSEcCtD
Carfilzomib—Hypoaesthesia—Mycophenolate mofetil—psoriasis	0.000714	0.00207	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Hydrocortisone—psoriasis	0.000714	0.00207	CcSEcCtD
Carfilzomib—Leukopenia—Mycophenolic acid—psoriasis	0.000709	0.00205	CcSEcCtD
Carfilzomib—Oedema peripheral—Mycophenolate mofetil—psoriasis	0.000707	0.00205	CcSEcCtD
Carfilzomib—Asthenia—Acitretin—psoriasis	0.000705	0.00204	CcSEcCtD
Carfilzomib—Sepsis—Methotrexate—psoriasis	0.000703	0.00204	CcSEcCtD
Carfilzomib—Vomiting—Calcitriol—psoriasis	0.000703	0.00203	CcSEcCtD
Carfilzomib—Headache—Calcitriol—psoriasis	0.000692	0.002	CcSEcCtD
Carfilzomib—Cough—Mycophenolic acid—psoriasis	0.000691	0.002	CcSEcCtD
Carfilzomib—Dyspnoea—Hydroxyurea—psoriasis	0.000688	0.00199	CcSEcCtD
Carfilzomib—Hypertension—Mycophenolic acid—psoriasis	0.000684	0.00198	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Triamcinolone—psoriasis	0.000676	0.00196	CcSEcCtD
Carfilzomib—Arthralgia—Mycophenolic acid—psoriasis	0.000674	0.00195	CcSEcCtD
Carfilzomib—Diarrhoea—Acitretin—psoriasis	0.000673	0.00195	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Triamcinolone—psoriasis	0.000673	0.00195	CcSEcCtD
Carfilzomib—Decreased appetite—Hydroxyurea—psoriasis	0.000671	0.00194	CcSEcCtD
Carfilzomib—Diarrhoea—Fluocinolone Acetonide—psoriasis	0.000671	0.00194	CcSEcCtD
Carfilzomib—Cardiac arrest—Prednisone—psoriasis	0.000669	0.00194	CcSEcCtD
Carfilzomib—Cardiac disorder—Mycophenolate mofetil—psoriasis	0.000666	0.00193	CcSEcCtD
Carfilzomib—Fatigue—Hydroxyurea—psoriasis	0.000665	0.00193	CcSEcCtD
Carfilzomib—Chills—Cyclosporine—psoriasis	0.00066	0.00191	CcSEcCtD
Carfilzomib—Pain—Hydroxyurea—psoriasis	0.00066	0.00191	CcSEcCtD
Carfilzomib—Constipation—Hydroxyurea—psoriasis	0.00066	0.00191	CcSEcCtD
Carfilzomib—Nausea—Calcitriol—psoriasis	0.000656	0.0019	CcSEcCtD
Carfilzomib—Hepatic failure—Methotrexate—psoriasis	0.000654	0.00189	CcSEcCtD
Carfilzomib—Dizziness—Acitretin—psoriasis	0.00065	0.00188	CcSEcCtD
Carfilzomib—Dizziness—Fluocinolone Acetonide—psoriasis	0.000648	0.00188	CcSEcCtD
Carfilzomib—Chills—Mycophenolate mofetil—psoriasis	0.000644	0.00187	CcSEcCtD
Carfilzomib—Infection—Mycophenolic acid—psoriasis	0.000642	0.00186	CcSEcCtD
Carfilzomib—Hypokalaemia—Prednisone—psoriasis	0.00064	0.00185	CcSEcCtD
Carfilzomib—Renal failure acute—Methotrexate—psoriasis	0.000637	0.00184	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mycophenolic acid—psoriasis	0.000633	0.00183	CcSEcCtD
Carfilzomib—Hyperglycaemia—Betamethasone—psoriasis	0.00063	0.00182	CcSEcCtD
Carfilzomib—Hyperglycaemia—Dexamethasone—psoriasis	0.00063	0.00182	CcSEcCtD
Carfilzomib—Vomiting—Acitretin—psoriasis	0.000625	0.00181	CcSEcCtD
Carfilzomib—Vomiting—Fluocinolone Acetonide—psoriasis	0.000623	0.0018	CcSEcCtD
Carfilzomib—Anorexia—Mycophenolic acid—psoriasis	0.000616	0.00178	CcSEcCtD
Carfilzomib—Muscle spasms—Cyclosporine—psoriasis	0.000616	0.00178	CcSEcCtD
Carfilzomib—Headache—Acitretin—psoriasis	0.000616	0.00178	CcSEcCtD
Carfilzomib—Headache—Fluocinolone Acetonide—psoriasis	0.000614	0.00178	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Betamethasone—psoriasis	0.000614	0.00178	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Dexamethasone—psoriasis	0.000614	0.00178	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Betamethasone—psoriasis	0.00061	0.00177	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Dexamethasone—psoriasis	0.00061	0.00177	CcSEcCtD
Carfilzomib—Body temperature increased—Hydroxyurea—psoriasis	0.00061	0.00177	CcSEcCtD
Carfilzomib—Back pain—Mycophenolate mofetil—psoriasis	0.000605	0.00175	CcSEcCtD
Carfilzomib—Muscle spasms—Mycophenolate mofetil—psoriasis	0.000601	0.00174	CcSEcCtD
Carfilzomib—Anaemia—Cyclosporine—psoriasis	0.000592	0.00171	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mycophenolic acid—psoriasis	0.000589	0.00171	CcSEcCtD
Carfilzomib—Insomnia—Mycophenolic acid—psoriasis	0.000585	0.00169	CcSEcCtD
Carfilzomib—Nausea—Acitretin—psoriasis	0.000584	0.00169	CcSEcCtD
Carfilzomib—Nausea—Fluocinolone Acetonide—psoriasis	0.000582	0.00169	CcSEcCtD
Carfilzomib—Anaemia—Mycophenolate mofetil—psoriasis	0.000578	0.00167	CcSEcCtD
Carfilzomib—Dyspnoea—Mycophenolic acid—psoriasis	0.000576	0.00167	CcSEcCtD
Carfilzomib—Leukopenia—Cyclosporine—psoriasis	0.000573	0.00166	CcSEcCtD
Carfilzomib—Neutropenia—Prednisone—psoriasis	0.000569	0.00165	CcSEcCtD
Carfilzomib—Decreased appetite—Mycophenolic acid—psoriasis	0.000562	0.00163	CcSEcCtD
Carfilzomib—Leukopenia—Mycophenolate mofetil—psoriasis	0.000559	0.00162	CcSEcCtD
Carfilzomib—Cough—Cyclosporine—psoriasis	0.000559	0.00162	CcSEcCtD
Carfilzomib—Fatigue—Mycophenolic acid—psoriasis	0.000557	0.00161	CcSEcCtD
Carfilzomib—Asthenia—Hydroxyurea—psoriasis	0.000554	0.0016	CcSEcCtD
Carfilzomib—Hypertension—Cyclosporine—psoriasis	0.000553	0.0016	CcSEcCtD
Carfilzomib—Pain—Mycophenolic acid—psoriasis	0.000553	0.0016	CcSEcCtD
Carfilzomib—Constipation—Mycophenolic acid—psoriasis	0.000553	0.0016	CcSEcCtD
Carfilzomib—Hyperglycaemia—Prednisone—psoriasis	0.000548	0.00159	CcSEcCtD
Carfilzomib—Arthralgia—Cyclosporine—psoriasis	0.000545	0.00158	CcSEcCtD
Carfilzomib—Cough—Mycophenolate mofetil—psoriasis	0.000545	0.00158	CcSEcCtD
Carfilzomib—Hypertension—Mycophenolate mofetil—psoriasis	0.00054	0.00156	CcSEcCtD
Carfilzomib—Acute coronary syndrome—Prednisone—psoriasis	0.000534	0.00155	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Clobetasol propionate—psoriasis	0.000534	0.0297	CbGdCrCtD
Carfilzomib—Arthralgia—Mycophenolate mofetil—psoriasis	0.000532	0.00154	CcSEcCtD
Carfilzomib—Neuropathy peripheral—Prednisone—psoriasis	0.000531	0.00154	CcSEcCtD
Carfilzomib—Diarrhoea—Hydroxyurea—psoriasis	0.000528	0.00153	CcSEcCtD
Carfilzomib—Infection—Cyclosporine—psoriasis	0.000519	0.0015	CcSEcCtD
Carfilzomib—Back pain—Triamcinolone—psoriasis	0.000519	0.0015	CcSEcCtD
Carfilzomib—Thrombocytopenia—Cyclosporine—psoriasis	0.000512	0.00148	CcSEcCtD
Carfilzomib—Body temperature increased—Mycophenolic acid—psoriasis	0.000511	0.00148	CcSEcCtD
Carfilzomib—Dizziness—Hydroxyurea—psoriasis	0.00051	0.00148	CcSEcCtD
Carfilzomib—Infection—Mycophenolate mofetil—psoriasis	0.000507	0.00147	CcSEcCtD
Carfilzomib—Hypertension—Prednisolone—psoriasis	0.000503	0.00146	CcSEcCtD
Carfilzomib—Thrombocytopenia—Mycophenolate mofetil—psoriasis	0.000499	0.00145	CcSEcCtD
Carfilzomib—Anorexia—Cyclosporine—psoriasis	0.000498	0.00144	CcSEcCtD
Carfilzomib—Hypertension—Hydrocortisone—psoriasis	0.000492	0.00142	CcSEcCtD
Carfilzomib—Vomiting—Hydroxyurea—psoriasis	0.000491	0.00142	CcSEcCtD
Carfilzomib—Anorexia—Mycophenolate mofetil—psoriasis	0.000486	0.00141	CcSEcCtD
Carfilzomib—Headache—Hydroxyurea—psoriasis	0.000483	0.0014	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Cyclosporine—psoriasis	0.000476	0.00138	CcSEcCtD
Carfilzomib—Neutropenia—Methotrexate—psoriasis	0.000475	0.00138	CcSEcCtD
Carfilzomib—Insomnia—Cyclosporine—psoriasis	0.000473	0.00137	CcSEcCtD
Carfilzomib—Upper respiratory tract infection—Methotrexate—psoriasis	0.000472	0.00137	CcSEcCtD
Carfilzomib—Cough—Triamcinolone—psoriasis	0.000468	0.00135	CcSEcCtD
Carfilzomib—Dyspnoea—Cyclosporine—psoriasis	0.000466	0.00135	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Mycophenolate mofetil—psoriasis	0.000465	0.00135	CcSEcCtD
Carfilzomib—Asthenia—Mycophenolic acid—psoriasis	0.000464	0.00134	CcSEcCtD
Carfilzomib—Hypertension—Triamcinolone—psoriasis	0.000463	0.00134	CcSEcCtD
Carfilzomib—Infection—Hydrocortisone—psoriasis	0.000462	0.00134	CcSEcCtD
Carfilzomib—Insomnia—Mycophenolate mofetil—psoriasis	0.000461	0.00134	CcSEcCtD
Carfilzomib—Nausea—Hydroxyurea—psoriasis	0.000458	0.00133	CcSEcCtD
Carfilzomib—Pneumonia—Methotrexate—psoriasis	0.000456	0.00132	CcSEcCtD
Carfilzomib—Dyspnoea—Mycophenolate mofetil—psoriasis	0.000455	0.00132	CcSEcCtD
Carfilzomib—Decreased appetite—Cyclosporine—psoriasis	0.000455	0.00132	CcSEcCtD
Carfilzomib—Fatigue—Cyclosporine—psoriasis	0.000451	0.00131	CcSEcCtD
Carfilzomib—Pain—Cyclosporine—psoriasis	0.000447	0.00129	CcSEcCtD
Carfilzomib—Constipation—Cyclosporine—psoriasis	0.000447	0.00129	CcSEcCtD
Carfilzomib—Renal failure—Methotrexate—psoriasis	0.000445	0.00129	CcSEcCtD
Carfilzomib—Decreased appetite—Mycophenolate mofetil—psoriasis	0.000443	0.00128	CcSEcCtD
Carfilzomib—Anorexia—Hydrocortisone—psoriasis	0.000443	0.00128	CcSEcCtD
Carfilzomib—Diarrhoea—Mycophenolic acid—psoriasis	0.000442	0.00128	CcSEcCtD
Carfilzomib—Pain—Mycophenolate mofetil—psoriasis	0.000436	0.00126	CcSEcCtD
Carfilzomib—Constipation—Mycophenolate mofetil—psoriasis	0.000436	0.00126	CcSEcCtD
Carfilzomib—Infection—Triamcinolone—psoriasis	0.000435	0.00126	CcSEcCtD
Carfilzomib—Insomnia—Prednisolone—psoriasis	0.00043	0.00125	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Beclomethasone—psoriasis	0.000428	0.0238	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Fluocinonide—psoriasis	0.000428	0.0238	CbGdCrCtD
Carfilzomib—Dizziness—Mycophenolic acid—psoriasis	0.000427	0.00124	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Hydrocortisone—psoriasis	0.000423	0.00123	CcSEcCtD
Carfilzomib—Insomnia—Hydrocortisone—psoriasis	0.00042	0.00122	CcSEcCtD
Carfilzomib—Hypertension—Betamethasone—psoriasis	0.00042	0.00122	CcSEcCtD
Carfilzomib—Hypertension—Dexamethasone—psoriasis	0.00042	0.00122	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Fluocinolone Acetonide—psoriasis	0.000416	0.0231	CbGdCrCtD
Carfilzomib—Body temperature increased—Cyclosporine—psoriasis	0.000413	0.0012	CcSEcCtD
Carfilzomib—Vomiting—Mycophenolic acid—psoriasis	0.000411	0.00119	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Clobetasol propionate—psoriasis	0.000407	0.0226	CbGdCrCtD
Carfilzomib—Pain—Prednisolone—psoriasis	0.000407	0.00118	CcSEcCtD
Carfilzomib—Headache—Mycophenolic acid—psoriasis	0.000405	0.00117	CcSEcCtD
Carfilzomib—Decreased appetite—Hydrocortisone—psoriasis	0.000404	0.00117	CcSEcCtD
Carfilzomib—Body temperature increased—Mycophenolate mofetil—psoriasis	0.000403	0.00117	CcSEcCtD
Carfilzomib—Fatigue—Hydrocortisone—psoriasis	0.000401	0.00116	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Triamcinolone—psoriasis	0.000399	0.00115	CcSEcCtD
Carfilzomib—Pain—Hydrocortisone—psoriasis	0.000397	0.00115	CcSEcCtD
Carfilzomib—Insomnia—Triamcinolone—psoriasis	0.000396	0.00115	CcSEcCtD
Carfilzomib—Infection—Dexamethasone—psoriasis	0.000394	0.00114	CcSEcCtD
Carfilzomib—Infection—Betamethasone—psoriasis	0.000394	0.00114	CcSEcCtD
Carfilzomib—Anaemia—Prednisone—psoriasis	0.000392	0.00113	CcSEcCtD
Carfilzomib—Dyspnoea—Triamcinolone—psoriasis	0.00039	0.00113	CcSEcCtD
Carfilzomib—Thrombocytopenia—Betamethasone—psoriasis	0.000389	0.00113	CcSEcCtD
Carfilzomib—Thrombocytopenia—Dexamethasone—psoriasis	0.000389	0.00113	CcSEcCtD
Carfilzomib—Nausea—Mycophenolic acid—psoriasis	0.000384	0.00111	CcSEcCtD
Carfilzomib—Anorexia—Betamethasone—psoriasis	0.000378	0.0011	CcSEcCtD
Carfilzomib—Anorexia—Dexamethasone—psoriasis	0.000378	0.0011	CcSEcCtD
Carfilzomib—Cardiac disorder—Methotrexate—psoriasis	0.000377	0.00109	CcSEcCtD
Carfilzomib—Fatigue—Triamcinolone—psoriasis	0.000377	0.00109	CcSEcCtD
Carfilzomib—Asthenia—Cyclosporine—psoriasis	0.000375	0.00109	CcSEcCtD
Carfilzomib—Pain—Triamcinolone—psoriasis	0.000374	0.00108	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Hydrocortisone—psoriasis	0.000371	0.0207	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Hydrocortisone—psoriasis	0.000371	0.0207	CbGdCrCtD
Carfilzomib—Body temperature increased—Hydrocortisone—psoriasis	0.000367	0.00106	CcSEcCtD
Carfilzomib—Asthenia—Mycophenolate mofetil—psoriasis	0.000366	0.00106	CcSEcCtD
Carfilzomib—Hypertension—Prednisone—psoriasis	0.000366	0.00106	CcSEcCtD
Carfilzomib—Chills—Methotrexate—psoriasis	0.000365	0.00106	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Dexamethasone—psoriasis	0.000362	0.00105	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Betamethasone—psoriasis	0.000362	0.00105	CcSEcCtD
Carfilzomib—Arthralgia—Prednisone—psoriasis	0.000361	0.00104	CcSEcCtD
Carfilzomib—Insomnia—Betamethasone—psoriasis	0.000359	0.00104	CcSEcCtD
Carfilzomib—Insomnia—Dexamethasone—psoriasis	0.000359	0.00104	CcSEcCtD
Carfilzomib—Diarrhoea—Cyclosporine—psoriasis	0.000358	0.00104	CcSEcCtD
Carfilzomib—Diarrhoea—Mycophenolate mofetil—psoriasis	0.000349	0.00101	CcSEcCtD
Carfilzomib—Body temperature increased—Triamcinolone—psoriasis	0.000346	0.001	CcSEcCtD
Carfilzomib—Dizziness—Cyclosporine—psoriasis	0.000346	0.001	CcSEcCtD
Carfilzomib—Decreased appetite—Betamethasone—psoriasis	0.000345	0.000999	CcSEcCtD
Carfilzomib—Decreased appetite—Dexamethasone—psoriasis	0.000345	0.000999	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Betamethasone—psoriasis	0.000345	0.0192	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Dexamethasone—psoriasis	0.000345	0.0192	CbGdCrCtD
Carfilzomib—Infection—Prednisone—psoriasis	0.000343	0.000995	CcSEcCtD
Carfilzomib—Back pain—Methotrexate—psoriasis	0.000342	0.000992	CcSEcCtD
Carfilzomib—Fatigue—Dexamethasone—psoriasis	0.000342	0.000991	CcSEcCtD
Carfilzomib—Fatigue—Betamethasone—psoriasis	0.000342	0.000991	CcSEcCtD
Carfilzomib—Pain—Betamethasone—psoriasis	0.00034	0.000983	CcSEcCtD
Carfilzomib—Pain—Dexamethasone—psoriasis	0.00034	0.000983	CcSEcCtD
Carfilzomib—Dizziness—Mycophenolate mofetil—psoriasis	0.000337	0.000977	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Triamcinolone—psoriasis	0.000337	0.0188	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Triamcinolone—psoriasis	0.000337	0.0188	CbGdCrCtD
Carfilzomib—Asthenia—Hydrocortisone—psoriasis	0.000333	0.000965	CcSEcCtD
Carfilzomib—Vomiting—Cyclosporine—psoriasis	0.000332	0.000963	CcSEcCtD
Carfilzomib—Anorexia—Prednisone—psoriasis	0.00033	0.000954	CcSEcCtD
Carfilzomib—Headache—Cyclosporine—psoriasis	0.000328	0.000948	CcSEcCtD
Carfilzomib—Anaemia—Methotrexate—psoriasis	0.000327	0.000948	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Fluocinonide—psoriasis	0.000326	0.0181	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Beclomethasone—psoriasis	0.000326	0.0181	CbGdCrCtD
Carfilzomib—Vomiting—Mycophenolate mofetil—psoriasis	0.000324	0.000939	CcSEcCtD
Carfilzomib—PSMB9—Betamethasone—Prednisone—psoriasis	0.00032	0.0178	CbGdCrCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisone—psoriasis	0.00032	0.0178	CbGdCrCtD
Carfilzomib—Headache—Mycophenolate mofetil—psoriasis	0.00032	0.000925	CcSEcCtD
Carfilzomib—Diarrhoea—Hydrocortisone—psoriasis	0.000318	0.000921	CcSEcCtD
Carfilzomib—Leukopenia—Methotrexate—psoriasis	0.000317	0.000918	CcSEcCtD
Carfilzomib—PSMB8—Diflorasone—Fluocinolone Acetonide—psoriasis	0.000317	0.0176	CbGdCrCtD
Carfilzomib—Musculoskeletal discomfort—Prednisone—psoriasis	0.000315	0.000912	CcSEcCtD
Carfilzomib—Dizziness—Prednisolone—psoriasis	0.000315	0.000911	CcSEcCtD
Carfilzomib—Asthenia—Triamcinolone—psoriasis	0.000314	0.000909	CcSEcCtD
Carfilzomib—Body temperature increased—Dexamethasone—psoriasis	0.000314	0.000909	CcSEcCtD
Carfilzomib—Body temperature increased—Betamethasone—psoriasis	0.000314	0.000909	CcSEcCtD
Carfilzomib—Insomnia—Prednisone—psoriasis	0.000313	0.000905	CcSEcCtD
Carfilzomib—PSMB9—Dexamethasone—Prednisolone—psoriasis	0.000312	0.0174	CbGdCrCtD
Carfilzomib—PSMB9—Betamethasone—Prednisolone—psoriasis	0.000312	0.0174	CbGdCrCtD
Carfilzomib—Nausea—Cyclosporine—psoriasis	0.000311	0.000899	CcSEcCtD
Carfilzomib—Cough—Methotrexate—psoriasis	0.000309	0.000895	CcSEcCtD
Carfilzomib—Dizziness—Hydrocortisone—psoriasis	0.000307	0.00089	CcSEcCtD
Carfilzomib—Nausea—Mycophenolate mofetil—psoriasis	0.000303	0.000877	CcSEcCtD
Carfilzomib—Arthralgia—Methotrexate—psoriasis	0.000301	0.000873	CcSEcCtD
Carfilzomib—Decreased appetite—Prednisone—psoriasis	0.000301	0.00087	CcSEcCtD
Carfilzomib—Fatigue—Prednisone—psoriasis	0.000298	0.000863	CcSEcCtD
Carfilzomib—Headache—Prednisolone—psoriasis	0.000298	0.000863	CcSEcCtD
Carfilzomib—Constipation—Prednisone—psoriasis	0.000296	0.000856	CcSEcCtD
Carfilzomib—Vomiting—Hydrocortisone—psoriasis	0.000295	0.000855	CcSEcCtD
Carfilzomib—Headache—Hydrocortisone—psoriasis	0.000291	0.000843	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Hydrocortisone—psoriasis	0.00029	0.0161	CbGdCrCtD
Carfilzomib—Dizziness—Triamcinolone—psoriasis	0.000289	0.000838	CcSEcCtD
Carfilzomib—Infection—Methotrexate—psoriasis	0.000287	0.000831	CcSEcCtD
Carfilzomib—Asthenia—Dexamethasone—psoriasis	0.000285	0.000825	CcSEcCtD
Carfilzomib—Asthenia—Betamethasone—psoriasis	0.000285	0.000825	CcSEcCtD
Carfilzomib—Thrombocytopenia—Methotrexate—psoriasis	0.000283	0.000819	CcSEcCtD
Carfilzomib—Nausea—Prednisolone—psoriasis	0.000283	0.000818	CcSEcCtD
Carfilzomib—Vomiting—Triamcinolone—psoriasis	0.000278	0.000806	CcSEcCtD
Carfilzomib—Nausea—Hydrocortisone—psoriasis	0.000276	0.000799	CcSEcCtD
Carfilzomib—Anorexia—Methotrexate—psoriasis	0.000275	0.000798	CcSEcCtD
Carfilzomib—Headache—Triamcinolone—psoriasis	0.000274	0.000794	CcSEcCtD
Carfilzomib—Body temperature increased—Prednisone—psoriasis	0.000273	0.000791	CcSEcCtD
Carfilzomib—Diarrhoea—Dexamethasone—psoriasis	0.000272	0.000787	CcSEcCtD
Carfilzomib—Diarrhoea—Betamethasone—psoriasis	0.000272	0.000787	CcSEcCtD
Carfilzomib—Musculoskeletal discomfort—Methotrexate—psoriasis	0.000263	0.000762	CcSEcCtD
Carfilzomib—Dizziness—Dexamethasone—psoriasis	0.000263	0.00076	CcSEcCtD
Carfilzomib—Dizziness—Betamethasone—psoriasis	0.000263	0.00076	CcSEcCtD
Carfilzomib—Insomnia—Methotrexate—psoriasis	0.000261	0.000757	CcSEcCtD
Carfilzomib—Nausea—Triamcinolone—psoriasis	0.00026	0.000753	CcSEcCtD
Carfilzomib—Dyspnoea—Methotrexate—psoriasis	0.000258	0.000746	CcSEcCtD
Carfilzomib—Vomiting—Dexamethasone—psoriasis	0.000252	0.000731	CcSEcCtD
Carfilzomib—Vomiting—Betamethasone—psoriasis	0.000252	0.000731	CcSEcCtD
Carfilzomib—Decreased appetite—Methotrexate—psoriasis	0.000251	0.000727	CcSEcCtD
Carfilzomib—Fatigue—Methotrexate—psoriasis	0.000249	0.000721	CcSEcCtD
Carfilzomib—Headache—Betamethasone—psoriasis	0.000249	0.00072	CcSEcCtD
Carfilzomib—Headache—Dexamethasone—psoriasis	0.000249	0.00072	CcSEcCtD
Carfilzomib—Asthenia—Prednisone—psoriasis	0.000248	0.000718	CcSEcCtD
Carfilzomib—Pain—Methotrexate—psoriasis	0.000247	0.000715	CcSEcCtD
Carfilzomib—PSMB8—Medrysone—Prednisolone—psoriasis	0.000244	0.0136	CbGdCrCtD
Carfilzomib—Diarrhoea—Prednisone—psoriasis	0.000237	0.000685	CcSEcCtD
Carfilzomib—Nausea—Dexamethasone—psoriasis	0.000236	0.000683	CcSEcCtD
Carfilzomib—Nausea—Betamethasone—psoriasis	0.000236	0.000683	CcSEcCtD
Carfilzomib—Dizziness—Prednisone—psoriasis	0.000229	0.000662	CcSEcCtD
Carfilzomib—Body temperature increased—Methotrexate—psoriasis	0.000228	0.000661	CcSEcCtD
Carfilzomib—Vomiting—Prednisone—psoriasis	0.00022	0.000637	CcSEcCtD
Carfilzomib—PSMB8—Betamethasone—Clobetasol propionate—psoriasis	0.000218	0.0121	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Clobetasol propionate—psoriasis	0.000218	0.0121	CbGdCrCtD
Carfilzomib—Headache—Prednisone—psoriasis	0.000217	0.000627	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Hydrocortisone—psoriasis	0.00021	0.0117	CbGdCrCtD
Carfilzomib—Asthenia—Methotrexate—psoriasis	0.000207	0.0006	CcSEcCtD
Carfilzomib—Nausea—Prednisone—psoriasis	0.000205	0.000595	CcSEcCtD
Carfilzomib—Diarrhoea—Methotrexate—psoriasis	0.000198	0.000572	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Betamethasone—psoriasis	0.000195	0.0109	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Dexamethasone—psoriasis	0.000195	0.0109	CbGdCrCtD
Carfilzomib—Dizziness—Methotrexate—psoriasis	0.000191	0.000553	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Triamcinolone—psoriasis	0.000191	0.0106	CbGdCrCtD
Carfilzomib—Vomiting—Methotrexate—psoriasis	0.000184	0.000532	CcSEcCtD
Carfilzomib—Headache—Methotrexate—psoriasis	0.000181	0.000524	CcSEcCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisone—psoriasis	0.000181	0.0101	CbGdCrCtD
Carfilzomib—PSMB8—Fluorometholone—Prednisolone—psoriasis	0.000177	0.00982	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Fluocinonide—psoriasis	0.000175	0.00973	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Beclomethasone—psoriasis	0.000175	0.00973	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Beclomethasone—psoriasis	0.000175	0.00973	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Fluocinonide—psoriasis	0.000175	0.00973	CbGdCrCtD
Carfilzomib—Nausea—Methotrexate—psoriasis	0.000172	0.000497	CcSEcCtD
Carfilzomib—PSMB8—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.00017	0.00945	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Fluocinolone Acetonide—psoriasis	0.00017	0.00945	CbGdCrCtD
Carfilzomib—PSMB8—Testosterone Propionate—Hydrocortisone—psoriasis	0.000162	0.00899	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Dexamethasone—psoriasis	0.000149	0.00827	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Betamethasone—psoriasis	0.000149	0.00827	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Triamcinolone—psoriasis	0.000145	0.00808	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Prednisone—psoriasis	0.000138	0.00767	CbGdCrCtD
Carfilzomib—PSMB8—Diflorasone—Prednisolone—psoriasis	0.000134	0.00748	CbGdCrCtD
Carfilzomib—PSMB8—Norethindrone—Hydrocortisone—psoriasis	0.000121	0.00674	CbGdCrCtD
Carfilzomib—PSMB10—Metabolism—CAT—psoriasis	0.000112	0.000266	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—CAT—psoriasis	0.000111	0.000264	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—HLA-A—psoriasis	0.000111	0.000264	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—HLA-A—psoriasis	0.000111	0.000263	CbGpPWpGaD
Carfilzomib—PSMB10—Adaptive Immune System—NFKB1—psoriasis	0.00011	0.000262	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—HLA-DRB1—psoriasis	0.00011	0.000261	CbGpPWpGaD
Carfilzomib—PSMB9—Adaptive Immune System—NFKB1—psoriasis	0.00011	0.00026	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—HLA-DRB1—psoriasis	0.000109	0.00026	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—VDR—psoriasis	0.000106	0.000251	CbGpPWpGaD
Carfilzomib—PSMB5—Gene Expression—VDR—psoriasis	0.000106	0.000251	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—VDR—psoriasis	0.000106	0.000251	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—ICAM1—psoriasis	0.000105	0.000251	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—ICAM1—psoriasis	0.000105	0.000249	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NFKBIA—psoriasis	0.000105	0.000249	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—VDR—psoriasis	0.000104	0.000248	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NFKBIA—psoriasis	0.000104	0.000247	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—APOE—psoriasis	0.000104	0.000246	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—APOE—psoriasis	0.000103	0.000245	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD8A—psoriasis	0.000102	0.000243	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD8A—psoriasis	0.000102	0.000243	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD8A—psoriasis	0.000102	0.000243	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD8A—psoriasis	0.000101	0.00024	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-B—psoriasis	9.84e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-B—psoriasis	9.84e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-B—psoriasis	9.84e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—SOCS1—psoriasis	9.84e-05	0.000234	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—SOCS1—psoriasis	9.79e-05	0.000233	CbGpPWpGaD
Carfilzomib—ABCB1—Allograft Rejection—TNF—psoriasis	9.76e-05	0.000232	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—NDUFA5—psoriasis	9.76e-05	0.000232	CbGpPWpGaD
Carfilzomib—PSMB10—Gene Expression—PPARG—psoriasis	9.73e-05	0.000231	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	9.7e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-B—psoriasis	9.7e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—CD4—psoriasis	9.69e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—CD4—psoriasis	9.69e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—CD4—psoriasis	9.69e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB9—Gene Expression—PPARG—psoriasis	9.68e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—NOS2—psoriasis	9.66e-05	0.00023	CbGpPWpGaD
Carfilzomib—PSMB8—Levonorgestrel—Hydrocortisone—psoriasis	9.63e-05	0.00536	CbGdCrCtD
Carfilzomib—PSMB9—Disease—NOS2—psoriasis	9.62e-05	0.000228	CbGpPWpGaD
Carfilzomib—PSMB8—Cytokine Signaling in Immune system—IL6—psoriasis	9.59e-05	0.000228	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—CD4—psoriasis	9.55e-05	0.000227	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-A—psoriasis	9.12e-05	0.000217	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-A—psoriasis	9.12e-05	0.000217	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-A—psoriasis	9.12e-05	0.000217	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CP—psoriasis	9.07e-05	0.000215	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-A—psoriasis	8.99e-05	0.000214	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CRP—psoriasis	8.7e-05	0.000207	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CRP—psoriasis	8.7e-05	0.000207	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CRP—psoriasis	8.7e-05	0.000207	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—APOE—psoriasis	8.68e-05	0.000206	CbGpPWpGaD
Carfilzomib—ABCB1—Transmembrane transport of small molecules—CARM1—psoriasis	8.65e-05	0.000205	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—APOE—psoriasis	8.64e-05	0.000205	CbGpPWpGaD
Carfilzomib—PSMB8—Betamethasone—Hydrocortisone—psoriasis	8.58e-05	0.00477	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Hydrocortisone—psoriasis	8.58e-05	0.00477	CbGdCrCtD
Carfilzomib—PSMB8—Immune System—CRP—psoriasis	8.58e-05	0.000204	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—TYK2—psoriasis	8.57e-05	0.000204	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—TYK2—psoriasis	8.53e-05	0.000203	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—CAT—psoriasis	8.47e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—CAT—psoriasis	8.47e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—CAT—psoriasis	8.47e-05	0.000201	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—HLA-A—psoriasis	8.42e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—HLA-A—psoriasis	8.42e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—HLA-A—psoriasis	8.42e-05	0.0002	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—CAT—psoriasis	8.35e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB5—Adaptive Immune System—NFKB1—psoriasis	8.35e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Adaptive Immune System—NFKB1—psoriasis	8.35e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Adaptive Immune System—NFKB1—psoriasis	8.35e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—HLA-DRB1—psoriasis	8.33e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—HLA-DRB1—psoriasis	8.33e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—HLA-DRB1—psoriasis	8.33e-05	0.000198	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—HLA-A—psoriasis	8.3e-05	0.000197	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CYP2S1—psoriasis	8.3e-05	0.000197	CbGpPWpGaD
Carfilzomib—PSMB10—Cell Cycle—TP53—psoriasis	8.24e-05	0.000196	CbGpPWpGaD
Carfilzomib—PSMB8—Adaptive Immune System—NFKB1—psoriasis	8.23e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—HLA-DRB1—psoriasis	8.21e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB9—Cell Cycle—TP53—psoriasis	8.2e-05	0.000195	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IFNG—psoriasis	8.03e-05	0.000191	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—ICAM1—psoriasis	7.99e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—ICAM1—psoriasis	7.99e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—ICAM1—psoriasis	7.99e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IFNG—psoriasis	7.99e-05	0.00019	CbGpPWpGaD
Carfilzomib—PSMB8—Dexamethasone—Betamethasone—psoriasis	7.97e-05	0.00443	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Dexamethasone—psoriasis	7.97e-05	0.00443	CbGdCrCtD
Carfilzomib—PSMB2—Immune System—NFKBIA—psoriasis	7.93e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NFKBIA—psoriasis	7.93e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NFKBIA—psoriasis	7.93e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—TYK2—psoriasis	7.91e-05	0.000188	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—ICAM1—psoriasis	7.88e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—TYK2—psoriasis	7.88e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—APOE—psoriasis	7.86e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—APOE—psoriasis	7.86e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—APOE—psoriasis	7.86e-05	0.000187	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NFKBIA—psoriasis	7.82e-05	0.000186	CbGpPWpGaD
Carfilzomib—PSMB8—Dexamethasone—Triamcinolone—psoriasis	7.78e-05	0.00433	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Triamcinolone—psoriasis	7.78e-05	0.00433	CbGdCrCtD
Carfilzomib—PSMB10—Immune System—CD4—psoriasis	7.75e-05	0.000184	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—APOE—psoriasis	7.75e-05	0.000184	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—CD4—psoriasis	7.72e-05	0.000183	CbGpPWpGaD
Carfilzomib—PSMB10—Metabolism—PPARG—psoriasis	7.56e-05	0.00018	CbGpPWpGaD
Carfilzomib—PSMB9—Metabolism—PPARG—psoriasis	7.53e-05	0.000179	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—SOCS1—psoriasis	7.46e-05	0.000177	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—SOCS1—psoriasis	7.46e-05	0.000177	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—SOCS1—psoriasis	7.46e-05	0.000177	CbGpPWpGaD
Carfilzomib—PSMB8—Betamethasone—Prednisone—psoriasis	7.39e-05	0.00411	CbGdCrCtD
Carfilzomib—PSMB8—Dexamethasone—Prednisone—psoriasis	7.39e-05	0.00411	CbGdCrCtD
Carfilzomib—PSMB5—Gene Expression—PPARG—psoriasis	7.37e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB1—Gene Expression—PPARG—psoriasis	7.37e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB2—Gene Expression—PPARG—psoriasis	7.37e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—SOCS1—psoriasis	7.35e-05	0.000175	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—NOS2—psoriasis	7.32e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—NOS2—psoriasis	7.32e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—NOS2—psoriasis	7.32e-05	0.000174	CbGpPWpGaD
Carfilzomib—PSMB8—Gene Expression—PPARG—psoriasis	7.27e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—LEP—psoriasis	7.26e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—APOE—psoriasis	7.26e-05	0.000173	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—LEP—psoriasis	7.23e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—APOE—psoriasis	7.23e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—NOS2—psoriasis	7.22e-05	0.000172	CbGpPWpGaD
Carfilzomib—PSMB8—Dexamethasone—Prednisolone—psoriasis	7.21e-05	0.00401	CbGdCrCtD
Carfilzomib—PSMB8—Betamethasone—Prednisolone—psoriasis	7.21e-05	0.00401	CbGdCrCtD
Carfilzomib—PSMB10—Disease—CD4—psoriasis	7.16e-05	0.00017	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—CD4—psoriasis	7.12e-05	0.000169	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—JUN—psoriasis	6.94e-05	0.000165	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—JUN—psoriasis	6.91e-05	0.000164	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NFKBIA—psoriasis	6.77e-05	0.000161	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NFKBIA—psoriasis	6.73e-05	0.00016	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—NFKB1—psoriasis	6.68e-05	0.000159	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—NFKB1—psoriasis	6.65e-05	0.000158	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—APOE—psoriasis	6.58e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—APOE—psoriasis	6.58e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—APOE—psoriasis	6.58e-05	0.000156	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—TYK2—psoriasis	6.5e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—TYK2—psoriasis	6.5e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—TYK2—psoriasis	6.5e-05	0.000154	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—APOE—psoriasis	6.49e-05	0.000154	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	6.43e-05	0.000153	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—TYK2—psoriasis	6.41e-05	0.000152	CbGpPWpGaD
Carfilzomib—PSMB2—Cell Cycle—TP53—psoriasis	6.25e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB5—Cell Cycle—TP53—psoriasis	6.25e-05	0.000148	CbGpPWpGaD
Carfilzomib—PSMB1—Cell Cycle—TP53—psoriasis	6.25e-05	0.000148	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	6.19e-05	0.000147	CbGpPWpGaD
Carfilzomib—PSMB8—Cell Cycle—TP53—psoriasis	6.16e-05	0.000146	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IFNG—psoriasis	6.08e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IFNG—psoriasis	6.08e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IFNG—psoriasis	6.08e-05	0.000145	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—STAT3—psoriasis	6e-05	0.000143	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—TYK2—psoriasis	6e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—TYK2—psoriasis	6e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—TYK2—psoriasis	6e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IFNG—psoriasis	6e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—STAT3—psoriasis	5.97e-05	0.000142	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—TYK2—psoriasis	5.91e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—CD4—psoriasis	5.88e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—CD4—psoriasis	5.88e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—CD4—psoriasis	5.88e-05	0.00014	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—CD4—psoriasis	5.79e-05	0.000138	CbGpPWpGaD
Carfilzomib—PSMB2—Metabolism—PPARG—psoriasis	5.73e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB5—Metabolism—PPARG—psoriasis	5.73e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB1—Metabolism—PPARG—psoriasis	5.73e-05	0.000136	CbGpPWpGaD
Carfilzomib—PSMB8—Metabolism—PPARG—psoriasis	5.65e-05	0.000134	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—psoriasis	5.62e-05	0.000133	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TYK2—psoriasis	5.54e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—STAT3—psoriasis	5.54e-05	0.000132	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TYK2—psoriasis	5.52e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—STAT3—psoriasis	5.52e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—LEP—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—LEP—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—APOE—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—APOE—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—LEP—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—APOE—psoriasis	5.5e-05	0.000131	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—APOE—psoriasis	5.43e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—LEP—psoriasis	5.43e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—CD4—psoriasis	5.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—CD4—psoriasis	5.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—CD4—psoriasis	5.42e-05	0.000129	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—CD4—psoriasis	5.35e-05	0.000127	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—JUN—psoriasis	5.26e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—JUN—psoriasis	5.26e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—JUN—psoriasis	5.26e-05	0.000125	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—JUN—psoriasis	5.18e-05	0.000123	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NFKBIA—psoriasis	5.13e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NFKBIA—psoriasis	5.13e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NFKBIA—psoriasis	5.13e-05	0.000122	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—NFKB1—psoriasis	5.06e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—NFKB1—psoriasis	5.06e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—NFKB1—psoriasis	5.06e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NFKBIA—psoriasis	5.06e-05	0.00012	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—NFKB1—psoriasis	4.99e-05	0.000119	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—CXCL8—psoriasis	4.83e-05	0.000115	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.82e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—CXCL8—psoriasis	4.8e-05	0.000114	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—STAT3—psoriasis	4.55e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—STAT3—psoriasis	4.55e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—STAT3—psoriasis	4.55e-05	0.000108	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—JUN—psoriasis	4.49e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—STAT3—psoriasis	4.48e-05	0.000107	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—JUN—psoriasis	4.46e-05	0.000106	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—NFKB1—psoriasis	4.32e-05	0.000103	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—NFKB1—psoriasis	4.3e-05	0.000102	CbGpPWpGaD
Carfilzomib—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	4.25e-05	0.000101	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TYK2—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TYK2—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TYK2—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—STAT3—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—STAT3—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—STAT3—psoriasis	4.2e-05	9.98e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Immune System—IL6—psoriasis	4.19e-05	9.96e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Immune System—IL6—psoriasis	4.17e-05	9.91e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TYK2—psoriasis	4.14e-05	9.84e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—STAT3—psoriasis	4.14e-05	9.84e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CARM1—psoriasis	4.05e-05	9.62e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—VEGFA—psoriasis	3.92e-05	9.31e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—VEGFA—psoriasis	3.9e-05	9.27e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—STAT3—psoriasis	3.88e-05	9.22e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Disease—IL6—psoriasis	3.87e-05	9.2e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—STAT3—psoriasis	3.86e-05	9.17e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Disease—IL6—psoriasis	3.85e-05	9.15e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—CXCL8—psoriasis	3.66e-05	8.69e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—CXCL8—psoriasis	3.66e-05	8.69e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—CXCL8—psoriasis	3.66e-05	8.69e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—CXCL8—psoriasis	3.61e-05	8.57e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—JUN—psoriasis	3.4e-05	8.08e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—JUN—psoriasis	3.4e-05	8.08e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—JUN—psoriasis	3.4e-05	8.08e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—JUN—psoriasis	3.35e-05	7.96e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—NFKB1—psoriasis	3.27e-05	7.77e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—NFKB1—psoriasis	3.27e-05	7.77e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—NFKB1—psoriasis	3.27e-05	7.77e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—NFKB1—psoriasis	3.23e-05	7.66e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Immune System—IL6—psoriasis	3.18e-05	7.55e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Immune System—IL6—psoriasis	3.18e-05	7.55e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Immune System—IL6—psoriasis	3.18e-05	7.55e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Immune System—IL6—psoriasis	3.13e-05	7.44e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—VEGFA—psoriasis	2.97e-05	7.06e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—VEGFA—psoriasis	2.97e-05	7.06e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—VEGFA—psoriasis	2.97e-05	7.06e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—TP53—psoriasis	2.96e-05	7.04e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—TP53—psoriasis	2.95e-05	7e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—STAT3—psoriasis	2.94e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—STAT3—psoriasis	2.94e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—STAT3—psoriasis	2.94e-05	6.99e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Disease—IL6—psoriasis	2.93e-05	6.97e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Disease—IL6—psoriasis	2.93e-05	6.97e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Disease—IL6—psoriasis	2.93e-05	6.97e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—VEGFA—psoriasis	2.93e-05	6.96e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—STAT3—psoriasis	2.9e-05	6.89e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Disease—IL6—psoriasis	2.89e-05	6.87e-05	CbGpPWpGaD
Carfilzomib—PSMB10—Signaling Pathways—IL6—psoriasis	2.71e-05	6.44e-05	CbGpPWpGaD
Carfilzomib—PSMB9—Signaling Pathways—IL6—psoriasis	2.7e-05	6.41e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—CAT—psoriasis	2.49e-05	5.92e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—TP53—psoriasis	2.24e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—TP53—psoriasis	2.24e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—TP53—psoriasis	2.24e-05	5.33e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—TP53—psoriasis	2.21e-05	5.26e-05	CbGpPWpGaD
Carfilzomib—PSMB5—Signaling Pathways—IL6—psoriasis	2.05e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB1—Signaling Pathways—IL6—psoriasis	2.05e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB2—Signaling Pathways—IL6—psoriasis	2.05e-05	4.88e-05	CbGpPWpGaD
Carfilzomib—PSMB8—Signaling Pathways—IL6—psoriasis	2.03e-05	4.81e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—APOE—psoriasis	1.94e-05	4.6e-05	CbGpPWpGaD
Carfilzomib—ABCB1—Metabolism—PPARG—psoriasis	1.69e-05	4.01e-05	CbGpPWpGaD
